{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T06:24:09Z","timestamp":1781504649447,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.eplepsyres.2019.106214","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T11:24:52Z","timestamp":1570101892000},"page":"106214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial"],"prefix":"10.1016","volume":"157","author":[{"given":"Nasim","family":"Tabrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Zarvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Cheraghmakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Alizadeh-Navaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2019.106214_bib0005","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.seizure.2005.09.003","article-title":"Long-term efficacy of levetiracetam for partial seizures","volume":"14","author":"Abou-Khalil","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0010","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2018.03.002","article-title":"Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center","volume":"82","author":"Ca\u00e7\u00e3o","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eplepsyres.2015.11.012","article-title":"Pharmacological outcomes in juvenile myoclonic epilepsy: support for sodium valproate","volume":"119","author":"Chowdhury","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.seizure.2017.08.007","article-title":"Antiepileptic drug trials for patients with drug resistant idiopathic generalised epilepsy: a meta-analysis","volume":"51","author":"Colleran","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0030","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14656566.2017.1328499","article-title":"Anticonvulsant drugs for generalized tonic-clonic epilepsy","volume":"18","author":"Coppola","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"issue":"Suppl 1","key":"10.1016\/j.eplepsyres.2019.106214_bib0035","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.yebeh.2013.01.001","article-title":"Management of juvenile myoclonic epilepsy","volume":"28","author":"Crespel","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1528-1167.2005.00329.x","article-title":"Levetiracetam in the treatment of idiopathic generalized epilepsies","volume":"46","author":"Gr\u00fcnewald","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1528-1167.2005.00309.x","article-title":"Epidemiology of idiopathic generalized epilepsies","volume":"46","author":"Jallon","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/epi.12057","article-title":"Reduced default mode network connectivity in treatment-resistant idiopathic generalized epilepsy","volume":"54","author":"Kay","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.yebeh.2015.11.009","article-title":"Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study","volume":"54","author":"Kowski","year":"2016","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0060","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0065","first-page":"29","article-title":"Drug treatment of uncontrolled seizures","volume":"5","author":"Mattson","year":"1992","journal-title":"Epilepsy Res. Suppl."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0070","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.seizure.2010.01.014","article-title":"Long-term efficacy of valproate versus lamotrigine in treatment of idiopathic generalized epilepsies in children and adolescents","volume":"19","author":"Mazurkiewicz-Be\u0142dzi\u0144ska","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2009.02230.x","article-title":"The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?","volume":"50","author":"Montouris","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0080","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"12","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0085","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.eplepsyres.2009.02.016","article-title":"Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies","volume":"85","author":"Rosenfeld","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0090","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/WNF.0000000000000177","article-title":"Levetiracetam and valproate retention rate in juvenile myoclonic epilepsy","volume":"39","author":"Sala-Padr\u00f3","year":"2016","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0095","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0100","article-title":"Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open. Accepted Author Manuscript."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2006.05.013","article-title":"Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy","volume":"71","author":"Specchio","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0110","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.seizure.2011.04.004","article-title":"Levetiracetam monotherapy--outcomes from an epilepsy clinic","volume":"20","author":"Stephen","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.seizure.2017.08.001","article-title":"Lamotrigine versus valproic acid monotherapy for generalised epilepsy: a meta-analysis of comparative studies","volume":"51","author":"Tang","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0120","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2011-300376","article-title":"KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy","volume":"84","author":"Trinka","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/NDT.S181886","article-title":"Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles","volume":"15","author":"Yi","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.eplepsyres.2019.106214_bib0130","first-page":"1","article-title":"Clinical features and treatment outcomes of Juvenile myoclonic epilepsy patients","volume":"0","author":"Zhang","year":"2019","journal-title":"Epilepsia Open"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119303729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119303729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:43:19Z","timestamp":1760276599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121119303729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":26,"alternative-id":["S0920121119303729"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106214","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levetiracetam in genetic generalized epilepsy: A prospective unblinded active-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106214","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106214"}}